CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CombiMatrix Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CombiMatrix Corporation
310 Goddard
Suite 150
Phone: (949) 753-0624p:949 753-0624 Irvine, CA  92618-4617  United States Fax: (949) 753-1504f:949 753-1504

This company was Merged or Acquired on 11/15/2017.
This company ceased filing statements with the SEC on 11/27/2017.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201712/31/2016YesYes--Yes

Industries
SIC Code Description
3826 Laboratory analytical instruments
8071 Medical laboratories

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Robert J.Jessup 68 3/15/2013 8/8/2010
President, Chief Executive Officer, Director MarkMcDonough 46 3/15/2013 2/28/2013
Chief Financial Officer, Treasurer, Secretary Scott R.Burell 52 11/1/2006 2/1/2000
4 additional Officers and Directors records available in full report.

Business Names
Business Name
CBMX
CombiMatrix Molecular Diagnostics, Inc.

General Information
Number of Employees: 55 (As of 12/31/2016)
Outstanding Shares: 2,943,892 (As of 11/3/2017)
Shareholders: 8
Stock Exchange: NASD
Federal Tax Id: 943373522
Fax Number: (949) 753-1504
Email Address: info@combimatrix.com


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 5, 2021